OncoC4 doses first participant in ovarian cancer therapy trial

OncoC4 has dosed the first participant in the Phase II combination study of its ONC-392 and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in platinum-resistant ovarian cancer (PROC) patients.